Mesoblast Limited (NASDAQ:MESO - Get Free Report) dropped 4.2% during mid-day trading on Monday . The company traded as low as $9.89 and last traded at $10.01. Approximately 78,595 shares were traded during mid-day trading, a decline of 71% from the average daily volume of 273,854 shares. The stock had previously closed at $10.44.
Analyst Upgrades and Downgrades
Separately, Cantor Fitzgerald upgraded Mesoblast to a "strong-buy" rating in a research note on Monday, March 31st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $18.00.
Check Out Our Latest Report on MESO
Mesoblast Stock Performance
The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.63 and a current ratio of 0.96. The stock's 50 day moving average price is $11.32 and its two-hundred day moving average price is $14.05.
Institutional Investors Weigh In On Mesoblast
Several institutional investors have recently modified their holdings of MESO. Barclays PLC acquired a new position in Mesoblast during the fourth quarter worth $38,000. Lindbrook Capital LLC boosted its position in shares of Mesoblast by 70.9% in the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock worth $43,000 after buying an additional 901 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in Mesoblast in the 4th quarter valued at about $50,000. BNP Paribas Financial Markets grew its stake in Mesoblast by 86,566.7% in the 4th quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock valued at $51,000 after acquiring an additional 2,597 shares during the last quarter. Finally, Advisors Preferred LLC increased its holdings in Mesoblast by 224.9% during the 1st quarter. Advisors Preferred LLC now owns 4,578 shares of the company's stock valued at $54,000 after acquiring an additional 3,169 shares in the last quarter. Hedge funds and other institutional investors own 1.43% of the company's stock.
Mesoblast Company Profile
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
